Tenaya Therapeutics (TNYA) Competitors $0.95 +0.09 (+9.96%) Closing price 04:00 PM EasternExtended Trading$0.92 -0.03 (-3.05%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. KOD, KMDA, ERAS, CGEM, CMPS, PRTA, TECX, PRTC, CYRX, and GOSSShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Kodiak Sciences (KOD), Kamada (KMDA), Erasca (ERAS), Cullinan Therapeutics (CGEM), COMPASS Pathways (CMPS), Prothena (PRTA), Tectonic Therapeutic (TECX), PureTech Health (PRTC), CryoPort (CYRX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors Kodiak Sciences Kamada Erasca Cullinan Therapeutics COMPASS Pathways Prothena Tectonic Therapeutic PureTech Health CryoPort Gossamer Bio Kodiak Sciences (NASDAQ:KOD) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Do analysts prefer KOD or TNYA? Kodiak Sciences presently has a consensus target price of $11.25, indicating a potential upside of 12.05%. Tenaya Therapeutics has a consensus target price of $6.25, indicating a potential upside of 560.05%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, KOD or TNYA? Kodiak Sciences has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Is KOD or TNYA more profitable? Tenaya Therapeutics' return on equity of -93.83% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -134.87% -59.58% Tenaya Therapeutics N/A -93.83%-75.66% Does the media prefer KOD or TNYA? In the previous week, Tenaya Therapeutics had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 15 mentions for Tenaya Therapeutics and 10 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.45 beat Tenaya Therapeutics' score of 0.30 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, KOD or TNYA? Kodiak Sciences is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$176.21M-$3.63-2.77Tenaya TherapeuticsN/AN/A-$111.13M-$0.96-0.99 Do insiders & institutionals have more ownership in KOD or TNYA? 89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTenaya Therapeutics beats Kodiak Sciences on 11 of the 13 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.34M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.9920.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book1.558.608.826.15Net Income-$111.13M-$54.65M$3.25B$265.06M7 Day Performance42.78%5.43%4.05%2.80%1 Month Performance33.10%6.75%4.32%1.68%1 Year Performance-66.54%31.59%36.25%29.59% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.0232 of 5 stars$0.95+10.0%$6.25+560.0%-71.8%$140.34MN/A-0.99110Analyst RevisionKODKodiak Sciences3.3003 of 5 stars$8.03+1.6%$9.00+12.1%+229.0%$423.66MN/A-2.2190News CoverageEarnings ReportAnalyst UpgradeGap UpKMDAKamada4.576 of 5 stars$7.34+3.1%$13.00+77.1%+33.0%$422.09M$167.24M25.31360News CoveragePositive NewsEarnings ReportShort Interest ↓ERASErasca2.4281 of 5 stars$1.48+5.7%$4.57+208.9%-37.7%$419.27MN/A-2.39120News CoverageEarnings ReportCGEMCullinan Therapeutics1.6343 of 5 stars$7.09-2.9%$30.00+323.1%-53.1%$418.42MN/A-2.2030Earnings ReportAnalyst RevisionCMPSCOMPASS Pathways2.5957 of 5 stars$4.34-1.1%$16.29+275.2%-38.8%$416.38MN/A-2.36120PRTAProthena3.5132 of 5 stars$7.67-0.3%$30.25+294.4%-59.7%$412.88M$10.34M-1.36130TECXTectonic Therapeutic2.2606 of 5 stars$22.11-0.9%$80.33+263.3%+36.2%$412.86MN/A-5.47120Earnings ReportPRTCPureTech Health2.7663 of 5 stars$17.15-0.6%$45.00+162.4%-22.7%$412.03M$4.32M0.00100News CoverageShort Interest ↓Gap UpCYRXCryoPort3.81 of 5 stars$8.09+7.0%$12.00+48.3%+10.7%$405.63M$228.38M6.081,186Gap DownGOSSGossamer Bio3.9062 of 5 stars$1.73-1.5%$8.50+390.5%+138.7%$394.05M$114.70M-2.80180Analyst Revision Related Companies and Tools Related Companies Kodiak Sciences Competitors Kamada Competitors Erasca Competitors Cullinan Therapeutics Competitors COMPASS Pathways Competitors Prothena Competitors Tectonic Therapeutic Competitors PureTech Health Competitors CryoPort Competitors Gossamer Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access